Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are up more than 6.5 percent Friday after the company reported first-quarter net revenue from EXONDYS 51 of $16.3 million and guided for $95 million in revenue for the full year, up from previous guidance of $80 million. In addition to the revenue beat, the stock's bullish trading action may be in response to another developing story.
In Other News...
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
In addition to the earnings report, Sarepta CEO Ed Kaye announced Thursday he will be stepping down from the position. At the same time, Sanofi SA (ADR) (NYSE:SNY) executive Jean-Paul Kress, M.D., announced he will be stepping down from Sarepta’s board of directors, citing “a possible conflict of interest associated with his future endeavors.”
TheStreet’s Adam Feuerstein speculates the timing of the two managerial shifts may not be coincidence; Sanofi may be setting the stage for a Sarepta buyout.
Sanofi recently failed in attempts to acquire Medivation Inc and Actelion Ltd (OTC:ALIOF), so the pharma giant is likely still on the hunt for targets. Feuerstein noted Sanofi’s Genzyme unit will soon open up a new headquarters in Boston, “right around the corner” from Sarepta’s headquarters.
Sarepta shareholders have been on a wild ride so far in 2017. Shares spiked from around $27 to above $39 in January before crashing back down to around $28 by mid-February. The stock then made another round-trip to $34.85 and back by early April before surging back above $36 following Q1 earnings.
Related Links:
Barron's Picks And Pans: Bank Stocks, O'Reilly Automotive, Sarepta And More
FDA Targets LifeVantage, 13 Other Companies Selling Illegal Cancer TreatmentsCrypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.